Multiple Endpoints in Clinical Trials: Biopharma Companies Seek More From FDA Draft Guidance
By Zachary Brennan -
Published 16 March 2017
Biopharmaceutical heavyweights – from Novartis to GlaxoSmithKline to Regeneron – are seeking additional clarification from the US Food and Drug Administration (FDA) on draft guidance on multiple endpoints in clinical trials, according to comments posted to the docket on Thursday.
Categories: News, US, FDA, Biologics and biotechnology, Clinical, Drugs, Postmarket surveillance
Tags: GlaxoSmithKline, Regeneron, Novartis, Teva, BIO, Celgene, AstraZeneca, clinical trial endpoints